Deficiency of GATA6 as a Molecular Tool to Assess the Risk for Cervical Cancer

Capo-chichi D. Callinice^1, , Alladagbin D. Jeanne¹, Brun Luc², Aguida Blanche¹, Agossou Komlan Vidéhouénou³, Anagbla Toussain⁴, Salmane Amidou², Xu Xiang-Xi⁵ and Sanni Ambaliou¹

¹Faculty of Sciences and technology (FAST) / Laboratory of Biochemistry and molecular biology (LBBM), Institute of Biomedical Sciences and Applications (ISBA) / University Abomey-Calavi (UAC), Benin

²Gynecology/obstetric service and CIPEC, CHDU Borgou, Parakou, Bénin

³Gynecology/obstetric and oncology services, CNHU, UAC, Cotonou, BENIN

⁴Gynecology/obstetric service, Hospital Mènontin, Cotonou, Benin

⁵Sylvester Cancer Center/Miller Medical School of Medicine, University of Miami, USA

Cite this paper:
Capo-chichi D. Callinice, Alladagbin D. Jeanne, Brun Luc, Aguida Blanche, Agossou Komlan Vidéhouénou, Anagbla Toussain, Salmane Amidou, Xu Xiang-Xi and Sanni Ambaliou. Deficiency of GATA6 as a Molecular Tool to Assess the Risk for Cervical Cancer. American Journal of Biomedical Research. 2014; 2(1):1-6. doi: 10.12691/ajbr-2-1-1

Abstract

Introduction: GATA6 is a transcription factor which has role in the induction of cell differentiation genes and the maintenance of the differentiated state of epithelial cells. GATA6 expression is lost in neoplastic ovarian epithelia cells and in ovarian carcinoma leading to abnormal nuclear morphology characteristic of most cancer cells. We investigated the profile of GATA6 in cells collected from cervical-uterine smears (CUS) of women in the gynecologic service of three hospitals in Benin. Objective: To utilize GATA6 as molecular marker for the screening of women at risk of developing cervical carcinomas. Methods: CUS were collected from forty (40) women coming for regular checkup (a) at the National University Hospital (CNHU) in Cotonou and (b) from the local hospital of Mènontin (HZ) in Cotonou (south of Benin); (c) forty other (40) CUS were collected from women coming for treatment against HIV1 in the service of gynecology of the Departmental University Hospital (CHDU) of Borgouin Parakou (north of Benin). GATA6 was analyzed in cells isolated from 80 CUS totally by the immunoblotting techniques. Results: In women from Cotonou, GATA6waspresent in 17/40 (42%) CUS, lightly expressed in 10/40 (25%) CUS and totally absent in /40 (32.5%) CUS. In the HIV1 infected women under treatment in Parakou, GATA6 was present in 8/40 (20%) CUS, lightly expressed in 13/40 (32.5%) and totally lost in 19/40 (47.5%) CUS. Conclusion: Our study showed that the loss of GATA6 in CUS was significantly higher in the population of women infected with HIV1 than in women from regular population in Cotonou. Thus the deficiency in GATA6 expression maybe utilizedas diagnostic tools to identify women at risk for developing cervical carcinomas regardless the infectious status before the onset of neoplasia.

Keywords:
GATA6 Cervical-Uterine smears cervical carcinomas

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Figures

References:

[1]	Zheng R., Blobel G.A. GATA Transcription Factors and Cancer. Genes & cancer, 1(12):1178-1188, December 2010.
[2]	Smith E.R., Cai K.Q., Capo-Chichi C.D., Xu X.X. Aberrant epithelialdifferentiation in ovarian cancer. Cancer treatment and research 149:147-163, 2009.
[3]	Bai H., Sakurai T., Godkin J.D., Imakawa K: expression and potential role of GATA factors in trophoblast development. The Journal of reproduction and development, 59(1):1-6,1 February 2013.
[4]	Capo-Chichi C.D., Rula M.E., Smedberg J.L., Vanderveer L., Parmacek M.S., Morrisey E.E., Godwin A.K., Xu X.X: Perception of differentiation cues by GATA factors in primitive endoderm lineage determination of mouse embryonic stem cells. Developmental biology 286(2):574-586. October 2005.
[5]	Haveri H., Westerholm-Ormio M., Lindfors K., Maki M., Savilahti E., Andersson L.C., Heikinheimo M. Transcription factors GATA-4 and GATA-6 in normal and neoplastic human gastrointestinal mucosa. BMC gastroenterology, 8(9):1-13, April 2008.
[6]	Belaguli, N.S., Aftab, M., Rigi, M., Zhang, M., Albo, D., Berger, D.H. GATA6 promotes colon cancer cell invasion by regulating urokinase plasminogen activator geneexpression. Neoplasia (New York, NY, 12(11):856-865, November 2010.
[7]	Molkentin, J.D. The zinc finger-containing transcription factors GATA-4, -5, and -6. Ubiquitously expressed regulators of tissue-specific geneexpression. The Journal of biological chemistry, 275(50):38949-38952, December 2000.
[8]	Capo-chichi, C.D., Roland, I.H., Vanderveer, L., Bao, R., Yamagata, T, Hirai, H, Cohen, C., Hamilton, T.C., Godwin, A.K., Xu, X.X. Anomalous expression of epithelial differentiation-determining GATA factors in ovarian tumorigenesis. Cancer research, 63(16):4967-4977, August 2003.
[9]	Caslini, C., Capo-chichi C.D., Roland I.H., Nicolas E., Yeung A.T., Xu X.X. Histone modifications silence the GATA transcription factor genes in ovarian cancer. Oncogene 2006, 25(39):5446-5461, August 2006.
[10]	Capo-chichi C.D., Cai K.Q., Testa J.R., Godwin A.K., Xu XX. Loss of GATA6 leads to nuclear deformation and aneuploidy in ovarian cancer. Molecular and cellular biology 2009, 29(17):4766-4777, September 2009.
[11]	Castellsagué X., Díaz M., de Sanjosé S., Muñoz N., Herrero R,. Franceschi S., Peeling R.W., Ashley R., Smith J.S., Snijders P.J., Meijer C.J., Bosch F.X. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. Journal of the National Cancer Institute, 98(5):303-315, Mars 2006.
[12]	Zhao F.H., Lewkowitz A.K., Chen F., Lin M.J., Hu S.Y., Zhang X., Pan Q.J., Ma J.F., Niyazi M., Li C.Q., Li S.M., Smith J.S., Belinson J.L., Qiao Y.L., Castle PE.: Pooled analysis of a self-sampling HPV DNA Test as a cervical cancer primary screening method. Journal of the National Cancer Institute, 104(3):178-188, February 2012.
[13]	McEachin M.D., Xu X.X., Santoianni R.A., Lawson D., Cotsonis G., Cohen C. GATA-4 and GATA-6 synthèse in human ovarian surface epithelial carcinoma. Appl Immunohistochem Mol Morphol, 16(2):153-158. March 2008.
[14]	Cai K.Q, Capo-Chichi C.D., Rula M.E., Yang D.H., Xu X.X. Dynamic GATA6expression in primitive endoderm formation and maturation in early mouse embryogenesis. Dev Dyn, 237(10):2820-2829, October 2008.
[15]	Yang D.H., Smith E.R., Cai K.Q., Xu X.X. C-Fos elimination compensates for disabled-2 requirement in mouse extraembryonic endoderm development. DevDyn, 238(3):514-523. March 2009.
[16]	Lin L., Bass A.J., Lockwood W.W., Wang Z., Silvers A.L, Thomas DG, Chang AC, Lin J, Orringer MB, Li W, Glover TW, Giordano TJ, Lam WL, Meyerson M, Beer DG. Activation of GATA binding protein 6 (GATA6) sustains oncogenic lineage-survival in esophageal adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 109(11):4251-4256, March 2012.
[17]	Cai K.Q., Caslini C., Capo-chichi C.D., Slater C., Smith E.R., Wu H., Klein-Szanto A.J., Godwin A.K., Xu X.X. Loss of GATA4 and GATA6 expression specifies ovarian cancer histological subtypes and precedes neoplastic transformation of ovarian surface epithelia. PloS one, 4(7):6454, July 2009.
[18]	Yang H., Lu M.M., Zhang L., Whitsett J.A., Morrisey E.E. GATA6 regulates differentiation of distal lung epithelium. Development (Cambridge, England), 129(9):2233-2246. May 2002.
[19]	Capo-Chichi C.D., Smedberg J.L., Rula M., Nicolas E., Yeung A.T., Adamo R.F., Frolov A., Godwin AK, Xu XX. Alteration of Differentiation Potentials by Modulating GATA Transcription Factors in Murine Embryonic Stem Cells.Stem Cells Int. 11; 2010:602068.